Drug intelligence / Profile preview

human umbilical cord-derived mesenchymal stem cells + bone marrow mononuclear cells

Development stage
Unknown
Lead developer
Translational Biosciences
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous, Intrathecal
01

Overview

This investigational cell therapy combination, developed by Translational Biosciences, consists of allogeneic human umbilical cord-derived mesenchymal stem cells (UC-MSC) and autologous bone marrow mononuclear cells (BMMC). It is currently being evaluated in Phase 1/2 clinical trials for the treatment of spinal cord injury (SCI). The therapeutic approach utilizes the synergistic effects of both cell types: UC-MSCs provide immunomodulatory and neurotrophic support to reduce secondary injury and promote a regenerative environment, while BMMCs, which include various progenitor populations, are intended to support revascularization and tissue repair. The treatment protocol involves a dual administration route, combining intravenous and intrathecal injections to optimize cell delivery to the central nervous system and systemic circulation.

Other names
UC-MSCBMMCUC-MSC + BMMCUC-MSC and BMMC

Beyond the preview

Go deeper on human umbilical cord-derived mesenchymal stem cells + bone marrow mononuclear cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells + bone marrow mononuclear cells.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call